Literature DB >> 18523258

Regulation of IL-17 in human CCR6+ effector memory T cells.

Hong Liu1, Christine Rohowsky-Kochan.   

Abstract

IL-17-secreting T cells represent a distinct CD4(+) effector T cell lineage (Th17) that appears to be essential in the pathogenesis of numerous inflammatory and autoimmune diseases. Although extensively studied in the murine system, human Th17 cells have not been well characterized. In this study, we identify CD4(+)CD45RO(+)CCR7(-)CCR6(+) effector memory T cells as the principal IL-17-secreting T cells. Human Th17 cells have a unique cytokine profile because the majority coexpress TNF-alpha but not IL-6 and a minor subset express IL-17 with IL-22 or IL-17 and IFN-gamma. We demonstrate that the cytokines that promote the differentiation of human naive T cells into IL-17-secreting cells regulate IL-17 production by memory T cells. IL-1beta alone or in association with IL-23 and IL-6 markedly increase IL-17(+) CCR6(+) memory T cells and induce IL-17 production in CCR6(-) memory T cells. We also show that T cell activation induces Foxp3 expression in T cells and that the balance between the percentage of Foxp3(+) and IL-17(+) T cells is inversely influenced by the cytokine environment. These studies suggest that the cytokine environment may play a critical role in the expansion of memory T cells in chronic autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523258     DOI: 10.4049/jimmunol.180.12.7948

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

Review 1.  Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage?

Authors:  Martin J Cannon; Hannah Goyne; Pamela J B Stone; Maurizio Chiriva-Internati
Journal:  Expert Opin Biol Ther       Date:  2011-01-28       Impact factor: 4.388

2.  Central and peripheral cytokines mediate immune-brain connectivity.

Authors:  Hugo O Besedovsky; Adriana del Rey
Journal:  Neurochem Res       Date:  2010-09-04       Impact factor: 3.996

3.  Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma.

Authors:  L J Chi; H T Lu; G L Li; X M Wang; Y Su; W H Xu; B Z Shen
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

Review 4.  Immune-mediated processes in neurodegeneration: where do we stand?

Authors:  Marc Fakhoury
Journal:  J Neurol       Date:  2016-02-12       Impact factor: 4.849

5.  Pleural mesothelial cells promote expansion of IL-17-producing CD8+ T cells in tuberculous pleural effusion.

Authors:  X Li; Q Zhou; W B Yang; X Z Xiong; R H Du; J C Zhang
Journal:  J Clin Immunol       Date:  2013-01-09       Impact factor: 8.317

6.  Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells.

Authors:  Kristin J Ness-Schwickerath; Chenggang Jin; Craig T Morita
Journal:  J Immunol       Date:  2010-05-14       Impact factor: 5.422

7.  Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology.

Authors:  Peter A Szabo; Ankur Goswami; Delfina M Mazzuca; Kyoungok Kim; David B O'Gorman; David A Hess; Ian D Welch; Howard A Young; Bhagirath Singh; John K McCormick; S M Mansour Haeryfar
Journal:  J Immunol       Date:  2017-02-20       Impact factor: 5.422

8.  Interleukin-27-mediated suppression of human Th17 cells is associated with activation of STAT1 and suppressor of cytokine signaling protein 1.

Authors:  Hong Liu; Christine Rohowsky-Kochan
Journal:  J Interferon Cytokine Res       Date:  2011-01-15       Impact factor: 2.607

9.  Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis.

Authors:  Jeffrey H Ruth; Christy C Park; M Asif Amin; Charles Lesch; Hubert Marotte; Shiva Shahrara; Alisa E Koch
Journal:  Arthritis Res Ther       Date:  2010-06-16       Impact factor: 5.156

Review 10.  Cellular immunotherapy for ovarian cancer.

Authors:  Martin J Cannon; Timothy J O'Brien
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.